Indian Army Medical Supplies Tender - Injections, Ointments, Tablets and Suspension Procurement 2026

Tender Overview

The Indian Army under the Department Of Military Affairs invites bids for a diverse range of medical consumables and formulations, covering Inj Lignocain HCL 2 percent vial of 30 ml, Inj Dexamethasone sodium phosphate 4 mg ampoule 2 ml, Inj Pheniramine Maleate vial 100 ml, Inj Diazepam 10 mg ampoule 2 ml, Tab Ivermectin 6 mg strip of 10, Suspension Pyrantel Pamoate 250 mg 5 ml, Inj Phytomenadione Vitamin K 1 mg 0.5 ml, Tacrolimus Ointment 0.03% 20 g, Betamethasone dipropionate 0.05% with Salicylic acid 3% tube 20 g, and Copper sulphate 1 kg packet. The total quantity and estimated value are not disclosed; however, the scope spans multiple dosage forms and topical preparations for military medical use, distributed under a single procurement exercise with a 25% quantity variation option. The event signals a structured government medical supply program requiring compliance with quality and regulatory standards and capability to deliver across the Indian Army network. The tender emphasizes delivery scalability, flexible ordering, and adherence to specified contract terms. Unique features include option-based quantity adjustments and extended delivery timing aligned to original/extended periods. The procurement aims to ensure uninterrupted medical stock for field and garrison use.

Technical Specifications & Requirements

• Product categories: injectable pharmaceuticals, oral suspensions, topical ointments, tablets, and mineral compounds
• Items include: Lignocaine HCL 2% injectable in 30 ml vials, Dexamethasone sodium phosphate 4 mg in 2 ml ampoules, Pheniramine Maleate in 100 ml vials, Diazepam 10 mg in 2 ml ampoules, Ivermectin 6 mg strips (10 per strip), Pyrantel Pamoate 250 mg suspension (5 ml), Phytomenadione Vitamin K1 1 mg (0.5 ml), Tacrolimus ointment 0.03% (20 g), Betamethasone dipropionate 0.05% with 3% salicylic acid (20 g), Copper sulphate (1 kg).
• No explicit numeric standards or certification codes are listed in the data; bidders must demonstrate compliance with general regulatory and medical safety norms applicable to Indian Army medical stock.
• The terms imply supply readiness, packaging conformity, cold-chain considerations for injectables where relevant, and compatibility with military medical procurement practices.
• Delivery terms allow quantities to vary by up to 25% of bid quantity, with potential extension of delivery period proportional to the quantity variation.
• The BOQ shows 10 items but lacks individual quantity and unit data; bidders should hedge by providing scalable quantities and unit rates.

Terms, Conditions & Eligibility

• EMD: Not disclosed in the data; bidders should prepare as per standard army EMD guidelines.
• Delivery: Delivery period linked to last date of original delivery order; extended period applies when option clause is invoked, with minimum 30 days, calculated as (Increased quantity / Original quantity) × Original delivery period.
• Payment terms: Not specified; bidders should anticipate standard government terms (milestone/against delivery).
• Documents: GST registration, PAN, manufacturing/authorization certificates, and prior experience in supplying medical formulations could be required; OEM authorizations may be needed for branded items.
• Quality/Compliance: No explicit standards listed; bidders should ensure GMP/WHO-compliant processes and pharmacopoeia alignment where applicable.
• Warranty/Penalties: Not specified; bidders should be prepared for standard performance penalties and warranty expectations typical of military supply contracts.
• Other clauses: The bid reserves the right to alter quantities by up to 25% during and after contract award; extended delivery timelines may apply.